PharmAla licenses exclusive US rights to ALA-002 to Jupiter Neurosciences for up to US$100 million
PUBT · 11h ago
Share
Listen to the news
- PharmAla licensed exclusive, perpetual U.S. rights to ALA-002 to Jupiter Neurosciences under a definitive agreement signed July 20, 2026.
- Total consideration up to about USD 100 million, including USD 3.33 million upfront paid in cash and Jupiter common stock.
- Milestones of up to USD 96.67 million tied to Phase 3 dosing, FDA approval, and U.S. sales thresholds up to USD 2 billion.
- A 3% royalty on U.S. net sales starts after the third commercialization milestone is achieved.
- PharmAla kept rights outside the U.S.; it will supply GMP-grade ALA-002 to Jupiter under a separate supply agreement.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pharmala Biotech Holdings Inc. published the original content used to generate this news brief on July 20, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved